Navidea, PETNet ink manufacturing deal
Article Thumbnail ImageAugust 21, 2013 -- Radiopharmaceutical developer Navidea Biopharmaceuticals and Siemens Healthcare subsidiary PETNet Solutions have signed a radiopharmaceutical manufacturing agreement.
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking

The deal covers Navidea's fluorine-18-labeled NAV4694 product, an investigational beta-amyloid PET imaging agent, Navidea said. Under the terms of the agreement, PETNet Solutions will manufacture NAV4694 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional PETNet locations next year, according to the firm.

NAV4694 is currently in phase II and III clinical trials in subjects who have signs or symptoms of cognitive impairment such as Alzheimer's disease, Navidea said.